BioCurity Pharmaceuticals Inc. offering is now closed and is no longer accepting investments.
INVEST IN BIOCURITY PHARMACEUTICALS INC. TODAY!
Because we believe that fighting cancer is hard enough!
$228,429.00 Raised
REASONS TO INVEST
Our proposed drugs are intended to provide cost effective protection for millions of cancer patients undergoing radiation therapy every year from the side effects of radiation therapy
Seven issued US patents with fully paid license for its technology in the US as well as international patents owned by the Company for our technology when patients are undergoing radiation combined with chemotherapy
BioCurity management is focused on meeting development milestones of the proposed drug (including a growing IP portfolio) and thereby increasing the valuation of BioCurity for investors with funds that are raised
ABOUT
HEADQUARTERS
110 Front Street, Suite 300
Jupiter, FL 33477
VALUATION
$36.32M
BioCurity is a biopharmaceutical company developing drugs to transform radiation therapy. Our mission is to prevent certain side effects of radiation therapy for cancer patients. The side effects range from burns to the skin for breast cancer patients to pneumonia for lung cancer patients. Damage to healthy tissue of cancer patients undergoing radiation therapy is a direct cause of these side effects. The proposed drugs under development are from BioCurity’s patented technology and have been preclinically tested for multiple cancers including breast, lung, head and neck, prostate and colorectal cancer. Consistent with our preclinical studies we intend to mitigate side effects of radiation therapy without impairing the effectiveness of radiation treatment.
TEAM
Dr. Cheryl Baker
Director and Scientific Founder
Sam Merchant
Chairman of the Board of Directors
Nancy Cass, Esq
Director
TERMS
BioCurity Pharmaceuticals Inc.
Overview
PRICE PER SHARE
$4.25
DEADLINE
May 1, 2021
VALUATION
$36.32M
AMOUNT RAISED
$228,429.00
Breakdown
MIN INVESTMENT
$510.00
MAX INVESTMENT
$106,998.00
MIN NUMBER OF SHARES OFFERED
2,352
OFFERING TYPE
Equity
ASSET TYPE
PREFERRED
SHARES OFFERED
Series 2 CF Convertible Preferred Stock
MAX NUMBER OF SHARES OFFERED
141,176
Maximum Number of Shares Offered subject to adjustment for bonus shares
Company | : | BioCurity Pharmaceuticals Inc. |
Corporate Address | : | 110 Front Street, Suite 300, Jupiter, FL 33477 |
Offering Minimum | : | $9,996.00 |
Offering Maximum | : | $599,998.00 |
Minimum Investment Amount(per investor) | : | $510.00 |
Terms
Offering Type | : | Equity |
Security Name | : | Series 2 CF Convertible Preferred Stock |
Minimum Number of Shares Offered | : | 2,352 |
Maximum Number of Shares Offered | : | 141,176 |
Price per Share | : | $4.25 |
Pre-Money Valuation | : | $36,320,126.00 |
Perks:
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below
The 10% Bonus for StartEngine Shareholders
BioCurity Pharmaceuticals Inc. will offer 10% additional bonus shares for all investments that are committed by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 or made at least two investments in StartEngine's own offerings.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series 2 CF Convertible Preferred Stock at $4.25 / share, you will receive 110 Series 2 CF Convertible Preferred Stock, meaning you'll own 110 shares for $425. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Salary payments made to one’s self, a friend or relative.
ALL UPDATES
04.30.21
JUST A FEW HOURS LEFT TO INVEST!
JOIN US AND TOGETHER WE CAN HELP CANCER PATIENTS WORLWIDE…
BECAUSE WE BELIEVE THAT FIGHTING CANCER IS HARD ENOUGH
ONLY A FEW HOURS LEFT!
https://www.startengine.com/biocurity
04.28.21
LAST CALL - BIOCURITY REGULATION CROWDFUNDING CAMPAIGN CLOSING IN JUST A FEW DAYS!
- BioCurity’s Regulation Crowdfunding opportunity for all investors (accredited and nonaccredited) closes in just a few days!
- Invest as LITTLE as $510.00
- Imagine…the one cancer patient you may be helping by preventing side effects from their life saving radiation treatment
- Don’t miss out and invest today! www.startengine.com/biocurity
BioCurity is a biotech company developing oncology supportive care drugs designed to prevent short and long-term radiation therapy side effects for cancer patients
04.21.21
END OF FIRST QUARTER UPDATE 2021
www.biocurity.com www.startengine.com/biocurity
END OF FIRST QUARTER UPDATE 2021
CLINCAL TEAM
CSSI Life Sciences (www.cssilifesciences.com) a full-service clinical development team is hard at work for BioCurity. From discovery to commercialization the group started the year recruiting and securing a stellar three member Scientific and Medical Advisory Board. See our website for more details www.biocurity.com. Further validating the science of BioCurity and the unmet need to prevent radiation side effects for cancer patients.
PATENT PORTFOLIO SUCCESSES FOR PRODUCT DEVELOPMENT
Provisional Patent Filed - BioCurity’s formulations of cerium oxide nanoparticles to prevent radiation therapy side effects for cancer patients undergoing radiation therapy has been filed by patent counsel. We now have 12 months to file the patent application that BioCurity can take globally. See our Press Release.
International Patents Received - BioCurity’s international patent entitled "Treatment of Cancer with a Combination of Radiation, Cerium Oxide Nanoparticles, and a Chemotherapeutic Agent” issued in Australia and Hong Kong. The claims cover the use of the cerium oxide nanoparticles for the reduction of radiation therapy side effects for patients with lung cancer treated only with radiation combined with at least one chemotherapeutic agent.
US Patent - BioCurity received a Notice of Allowance in the United States Patent Office for its pending application covering claims directed to a method of treating or protecting skin or salivary gland tissue from ionizing radiation induced dermatitis or reduced salivary production by topically applying a cerium oxide nanoparticle cream composition to the skin.
To learn how to become an investor in BioCurity’s Regulation Crowdfunding campaign closing soon - www.startengine.com/biocurity
Be sure to follow us on LinkedIn and Facebook
Team BioCurity – www.biocurity.com
04.16.21
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
04.01.21
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
03.11.21
BioCurity Summary of Updates since January – March 2021
Summary of Updates since January – March 2021
- CLINICAL TEAM SECURED - CSSi LifeSciences www.cssilifesciences.com has been retained by BioCurity as a full-service clinical development team with experience in bringing hundreds of drugs from discovery to commercialization. This is an economically efficient model for BioCurity and provides access to a deep bench of professionals. Please go to the CSSi website and see the depth of their team led by Jim Sergi. With Jim’s leadership and experience in supportive care oncology projects management is pleased to have retained CSSi and what a positive way to start out the New Year. Watch for updates!
- SCIENTIFIC AND MEDICAL ADVISORY BOARD LAUNCHED - After much research and discussions internally, the first two members of the BioCurity Scientific and Medical Advisory Board have joined the BioCurity team. We could not be more thrilled than to welcome Dr. Chirag Shah, MD of Cleveland Clinic and Dr. Mark Ratain, MD of University of Chicago. Each member of the Scientific and Medical Advisory Board provides their unique experience. Dr. Shah, as a radiation oncologist with a patient centric view of treatment and Dr. Ratain, whose recognition as a Phase 1 expert will balance well with the rest of the BioCurity team.
- PATENT - BioCurity received an issuance from the Hong Kong Patent Office for BioCurity's HK patent #1237267B entitled "Treatment of Cancer with a Combination of Radiation, Cerium Oxide Nanoparticles, and a Chemotherapeutic Agent." This Hong Kong patent covers the use of cerium oxide nanoparticles for the reduction of side effects caused by radiation therapy for lung and pancreatic cancer patients receiving a combination of therapeutically effective doses of radiation therapy and chemotherapy as part of their treatment regimen.
We thank all of you who have become shareholders in BioCurity. The journey is underway. Please share information about BioCurity’s Crowdfunding Campaign. www.startengine.com/biocurity
Be sure to follow us on LinkedIn and Facebook
Team BioCurity – www.biocurity.com
03.05.21
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
02.26.21
BioCurity Announces Issuance of Hong Kong Patent
BioCurity Pharmaceuticals Inc. ('BioCurity') Announces Issuance of Hong Kong Patent for Reduction of Side Effects Caused by Radiation Therapy Combined with Chemotherapy
JUPITER, Fla., - BioCurity, a private preclinical biotech company with a mission to prevent radiation therapy's side effects for cancer patients and survivors, received an issuance from the Hong Kong Patent Office for BioCurity's HK patent #1237267B entitled "Treatment of Cancer with a Combination of Radiation, Cerium Oxide Nanoparticles, and a Chemotherapeutic Agent." This Hong Kong patent covers the use of cerium oxide nanoparticles for the reduction of side effects caused by radiation therapy for lung and pancreatic cancer patients receiving a combination of therapeutically effective doses of radiation therapy and chemotherapy as part of their treatment regimen. BioCurity exclusively owns its international patents, which currently exist in China, Japan, Europe, and Hong Kong.
About BioCurity Pharmaceuticals Inc.
BioCurity's proprietary technology is designed to protect normal cells from radiation damage without impacting the effectiveness of radiation treatment. Globally, approximately 6 million of the 18 million annually diagnosed new cancer patients receive radiation. The lack of a drug to protect cancer patients' internal tissues and skin from the short and long-term side effects of radiation therapy is a global unmet patient need. Invest in BioCurity through its Regulation Crowdfunding Campaign to support its drug development. Visit BioCurity's website and follow them on LinkedIn and Facebook.
This news release contains forward-looking statements, including those relating to the product development of BioCurity Pharmaceuticals Inc. (the "Company" or "BioCurity"), clinical and regulatory timelines, market opportunity and other statements that are predictive in nature, or that depend upon or refer to future events or conditions. Forward-looking statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this news release. BioCurity's lead product candidate is in preclinical development and is not for sale or use. This news release is not an offer to buy any securities of the Company.
02.24.21
Notice of Material Change in Offering
[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the BioCurity Pharmaceuticals Inc. offering. Here's an excerpt describing the specifics of the change:
BioCurity Pharmaceuticals Inc. extended the length of their campaign.
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
02.12.21
Notice of Funds Disbursement
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
REWARDS
$510.00
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
JOIN THE DISCUSSION
0/2500
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
